Dr Boreham's Crucible: Imricor Medical Systems
Imricor is a player in a global catheter ablation market worth $US5.5 billion and growing at a compound rate of just over 8% a year
Source: fnarena.com
Stay updated with breaking news from Tim Boreham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imricor is a player in a global catheter ablation market worth $US5.5 billion and growing at a compound rate of just over 8% a year
Pharmaxis might be two clinical studies away from rehabilitation, reports Tim Boreham
Tim Boreham reports the world might soon be scrambling for helium, while also identifying three ASX-listed exposures
Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd
Vaxxas is still unlisted, but worth highlighting as yet another Australian success story looks to be unfolding, reports Tim Boreham